Pay in 4 interest-free payments of $5.50 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
This also means that some of the improvements persist after discontinuation, because the new synaptic connections Dihexa helped create remain in place
For broader peptide safety context, see the peptide safety guide
Low-dose BPC-157 (150-250mcg daily) with occasional TB-500 (2mg monthly) provides ongoing healing support without intensive resource use
Reported Adverse Effects In the available case series and observational literature, the most commonly reported adverse effects include: Injection-site redness or mild induration in approximately 8 to 12% of users Transient nausea, most often associated with oral formulations or higher injectable doses Lightheadedness in a small number of patients shortly after injection (under 2% of reported cases) Vivid dreams or mild sleep changes, reported anecdotally by a subset of users with no clear mechanistic explanation No published human case reports as of July 2025 document serious organ toxicity, malignancy, or endocrine disruption attributable to BPC-157
4.5 mg cohort 69.9 kg / BMI 23.2 (the leanest cohorts)
US$ 27.57
US$ 28.88
US$ 21.22
US$ 21.61
US$ 24.47
US$ 23.15
US$ 28.72
US$ 26.15
US$ 21.18
